cediranib and olaparib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Platinum Resistant Ovarian Cancer
Conditions
Recurrent Platinum Resistant Ovarian Cancer
Trial Timeline
Jan 17, 2017 → Mar 16, 2021
NCT ID
NCT02889900About cediranib and olaparib
cediranib and olaparib is a phase 2 stage product being developed by AstraZeneca for Recurrent Platinum Resistant Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02889900. Target conditions include Recurrent Platinum Resistant Ovarian Cancer.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Platinum Resistant Ovarian Cancer were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02889900 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent Platinum Resistant Ovarian Cancer